항생제
Atazanavir/Cobicistat

Atazanavir/Cobicistat

Spectrum Of Activity

General Information

HIV infection; Adjunct

Perform renal function tests, including estimated CrCl, SCr, and urinalysis with microscopic examination.

Monitor viral load, CD4 cell counts, and hepatitis B screening at baseline and with modification of ARV treatment.

Perform hepatitis C antibody testing prior to initiation or modification of ARV treatment.

Perform hepatic function test in patients with underlying hepatitis B or C viral infections or markedly elevated transaminases.

Monitor ALT, AST, and total bilirubin at baseline and with modification of ARV treatment.

Obtain fasting blood glucose or HbA1C, fasting lipid profile, and CBC with a differential.

Obtain basic chemistry including serum sodium, potassium, bicarbonate, chloride, BUN, creatinine, and creatinine-based estimated glomerular filtration rate.

Common

  • Rash
  • Nausea
  • Headache
  • Scleral icterus

Serious

  • Abnormal cadiac conduction
  • Atrioventricular block
  • Erythema multiforme
  • Stevens-Johnson syndrome
  • Toxic epidermal necrolysis
  • Diabetes mellitus
  • Hyperglycemia
  • Gallstone
  • Jaundice
  • Immune reconstitution disorder
  • Rhabdomyolysis
  • Acute renal failure
  • Chronic kidney disease
  • Fanconi syndrome

Contraindications:

  • CYP3A inhibitors and substrates
  • CYP3A4 inhibitors and substrates
  • QT interval prolonging drugs
  • Ergot derivatives

Multiple drug-drug interactions

Antimicrobial class: Antiretroviral, Protease inhibitor

Pregnancy category: Do not initiate

Average serum half life: 7.5 hours (Atazanavir), 3-4 hours (Cobicistat)

Precautions: ECG monitoring should be considered in patients with preexisting conduction-system disease.

Not recommended in treatment-experienced patients with endstage renal disease managed with hemodialysis.

Discontinue use if severe rash develops.